Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2523355 (litronesib) in Advanced Solid Tumors
NCT01059643Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of litronesib in ovarian cancer, non-small cell lung cancer (NSCLC), prostate cancer (PCa), colorectal cancer (CRC), gastric cancer (GC), sponsored by Eli Lilly and Company. Started Apr 2011; status: completed.
02
Drugs
litronesib
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)prostate cancer (PCa)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT01059643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059643.